New Guidance on Investigational Medicinal Products (IMPs) and Non Investigational Medicinal products (NIMPs)
The EU Commission has published a revision of the Guidance on Investigational Medicinal Products (IMPs) and Non investigational Medicinal Products (NIMPs), which had been published in 2007, completing the detailed guidance CT-1. The main change relates to point 3.3 and the additional annex 2 setting out documentation requirements for NIMPs in the application dossier.
In 3.3., it is pointed out that documentation requirements in the application dossier for IMPs also apply to NIMPs. However, depending on the knowledge of the NIMP, documentation can be reduced to a so called 'simplified dossier' described in detail in Annex 2 of the document. To determine the required data, a risk-based approach needs to be applied.
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
03.04.2025Update on the ICH M11 CeSHArP Technical Specification
03.04.2025EU Map to Clinical Trials
03.04.2025EMA Concept Paper on Model Informed Drug Development
20.03.2025End of the Transition Period for Clinical Trials
11.02.2025Final ICH E6(R3) Guideline on GCP released
11.02.2025FDA issues Draft Guidance on Handling Protocol Deviations in Clinical Trials